Here are four takeaways:
1. The Superion device is indicated for moderate lumbar spinal stenosis.
2. The approval order follows a February FDA Advisory Panel vote that Superion demonstrated safety, efficacy and a favorable risk benefit profile in an investigational device exemption trial.
3. Superion has been successfully implanted in more than 2,000 patients around the world and will soon be available in the United States.
4. Founded in 2005, VertiFlex is a privately held medical device company dedicated to developing minimally invasive solutions for the treatment of lumbar spinal stenosis.
More articles on devices:
6 key trends in the North American joint reconstruction market
Orchid opens new India plant—5 things to know
8 trends in the China orthopedic instrument market
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
